Alterations in cardiac energy metabolism contribute to the severity of heart failure. However,
the energy metabolic changes that occur in heart failure are complex and are dependent not …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …

Background: The human heart primarily metabolizes fatty acids, and this decreases as
alternative fuel use rises in heart failure with reduced ejection fraction (HFrEF). Patients with …

Metabolic perturbations underlie a variety of cardiovascular disease states; yet, metabolic
interventions to prevent or treat these disorders are sparse. Ketones carry a negative clinical …

The ketone bodies beta-hydroxybutyrate and acetoacetate are hepatically produced
metabolites catabolized in extrahepatic organs. Ketone bodies are a critical cardiac fuel and …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

The gut microbiome and its metabolites are increasingly implicated in several
cardiovascular diseases, but their role in human myocardial infarction (MI) injury responses …

Cardiac metabolism is vital for heart function. Given that cardiac contraction requires a
continuous supply of ATP in large quantities, the role of fuel metabolism in the heart has …

Heart failure (HF) is marked by distinctive changes in myocardial uptake and utilization of
energy substrates. Among the different types of HF, HF with preserved ejection fraction …